European equities traded in the US as American depositary receipts were lower late Thursday morning, declining 0.56% to 1,718.19 on the S&P Europe Select ADR Index, which is still up 0.2% for the week so far.

From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and pharmaceutical company Novo Nordisk (NVO), which rose 4.2% and 2.6%, respectively. They were followed by internet advertising firm Criteo (CRTO) and internet browser company Opera (OPRA), which were up 2.1% and 1.8%, respectively.

The decliners from continental Europe were led by lender Banco Santander (SAN) and biopharmaceutical company Cellectis (CLLS), which dropped 1.6% and 1.2%, respectively. They were followed by lenders Banco Bilbao Vizcaya Argentaria (BBVA) and ING Groep (ING), which were off 0.9% and 0.4%, respectively.

The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and software firm Endava (DAVA), which advanced 3.2% and 3.1%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Trinity Biotech (TRIB), which increased 2.3% and 1.8%, respectively.

The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and lender Lloyds Banking Group (LYG), which lost 4.9% and 1.5%, respectively. They were followed by lender Barclays (BCS) and utilities company National Grid (NGG), which were down 1.4% each.